A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 22 sites in 5 countries. Open to participants aged 2 Years to 5 Years. Per ClinicalTrials.gov, last updated 2023-06-28.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.
Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one is the 15th largest by enrollment, is one of 5 that started in 2020, is one of 19 in phase 3, and was the 11th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 2 Years to 5 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 5 started in 2020.
This study's enrollment of 83 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 120 across the 23 interventional studies. Of the 18 that completed or were terminated, 17 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 23 have an industry lead sponsor. The 4 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 52nd largest by enrollment of the 116 interventional ones that give a count, is one of 5 that started in 2020, is one of 62 in phase 3, and was the 95th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
2 of the studies testing elexacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies testing elexacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) triple combination therapy in CF subjects 2 through 5 years of age.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants weighing greater than or equal to (\>=)14 kilograms (kg) at screening received elexacaftor (ELX) 100 milligrams (mg) once daily (qd)/tezacaftor (TEZ) 50 mg qd/ivacaftor (IVA) 75 mg every 12 hours (q12h) in the treatment period for 15 days.
Drug: ELX/TEZ/IVA · Drug: IVA
Participants weighing (\>=)14 kg at screening received ELX 100 mg qd/TEZ 50 mg qd/IVA 75 mg q12h. Participants weighing (\>=)10 kg to less than (\<)14 kg received ELX 80 mg qd/TEZ 40 mg qd/IVA 60 mg once every morning (qAM) and 59.5 mg once every evening (qPM) in the treatment period for 24 weeks.
Drug: ELX/TEZ/IVA · Drug: IVA
Drug pages: Elexacaftor · Tezacaftor · Ivacaftor
Fixed dose combination granules for oral administration.
Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor
Granules for oral administration.
Also known as: VX-770, ivacaftor
Part A: Observed Pre-dose Concentration (Ctrough) of ELX,TEZ,IVA, and Relevant Metabolites
Time frame: From Day 1 through Day 15
Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: From Day 1 up to Day 43
Part B: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: From Day 1 up to Week 28
Part B: Observed Pre-dose Plasma Concentration (Ctrough) of ELX,TEZ,IVA and Relevant Metabolites
Time frame: From Day 1 through Week 16
Part B: Absolute Change in Sweat Chloride (SwCl)
Sweat samples were collected using an approved collection device.
Time frame: From Baseline through Week 24
Part B: Absolute Change in Lung Clearance Index 2.5 (LCI 2.5)
The LCI2.5 index is the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting values and is calculated by dividing the sum of exhaled tidal breaths (cumulative exhaled volume (CEV)) by simultaneously measured functional residual capacity (FRC). An LCI of 7.5 and below is normal; values greater than 7.5 are abnormal. LCI is able to detect abnormalities in lung function earlier than more traditional modalities such as spirometry.
Time frame: From Baseline through Week 24
The study was conducted in 2 parts, Part A and Part B. The Participant flow was planned to be presented for the overall treatment arms (i.e. Part A and Part B), irrespective of weight-based dose regimen.
| Milestone | Part A: ELX/TEZ/IVA | Part B: ELX/TEZ/IVA |
|---|---|---|
| Started | 18 | 0 |
| Completed | 18 | 0 |
| Not completed | 0 | 0 |
| Milestone | Part A: ELX/TEZ/IVA | Part B: ELX/TEZ/IVA |
|---|---|---|
| Started | 0 | 75 |
| Completed | 0 | 74 |
| Not completed | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| micrograms per milliliter (mcg/ml) | Part A: ELX/TEZ/IVA |
|---|---|
| Day 1: ELX | 0.00 ± 0.00 |
| Day 8: ELX | 3.44 ± 2.09 |
| Day 15: ELX | 3.69 ± 2.11 |
| Day 1: ELX-M23 | 0.00 ± 0.00 |
| Day 8: ELX-M23 | 2.39 ± 1.65 |
| Day 15: ELX-M23 | 2.47 ± 1.65 |
| Day 1: TEZ | 0.00 ± 0.00 |
| Day 8: TEZ | 1.86 ± 1.07 |
| Day 15: TEZ | 1.85 ± 1.10 |
| Day 1: TEZ-M1 | 0.00 ± 0.00 |
| Day 8: TEZ-M1 | 6.42 ± 1.42 |
| Day 15: TEZ-M1 | 7.68 ± 1.52 |
| Day 1: IVA | 0.00 ± 0.00 |
| Day 8: IVA | 0.702 ± 0.503 |
| Day 15: IVA | 0.746 ± 0.526 |
| Day 1: IVA-M1 | 0.00 ± 0.00 |
| Day 8: IVA-M1 | 1.78 ± 0.990 |
| Day 15: IVA-M1 | 1.91 ± 0.990 |
| participants | Part A: ELX/TEZ/IVA |
|---|---|
| Participants with TEAEs | 15 |
| Participants with SAEs | 0 |
| participants | Part B: ELX/TEZ/IVA |
|---|---|
| Participants with TEAEs | 74 |
| Participants with SAEs | 2 |
| micrograms per milliliter (mcg/ml) | Part B: ELX/TEZ/IVA (≥10 kg to <14 kg) | Part B: ELX/TEZ/IVA (≥14 kg) |
|---|---|---|
| Day 15: ELX | 2.91 ± 1.38 | 3.87 ± 2.75 |
| Week 4: ELX | 3.13 ± 1.90 | 3.56 ± 2.19 |
| Week 12: ELX | 2.48 ± 1.65 | 3.49 ± 2.22 |
| Week 16: ELX | 3.01 ± 1.11 | 3.18 ± 2.19 |
| Day 15: ELX-M23 | 1.85 ± 1.12 | 2.33 ± 1.87 |
| Week 4: ELX-M23 | 2.32 ± 2.01 | 2.22 ± 1.66 |
| Week 12: ELX-M23 | 1.48 ± 1.27 | 2.17 ± 1.69 |
| Week 16: ELX-M23 | 1.73 ± 0.828 | 1.94 ± 1.58 |
| Day 15: TEZ | 1.73 ± 0.666 | 2.14 ± 1.72 |
| Week 4: TEZ | 1.62 ± 0.716 | 1.79 ± 0.947 |
| Week 12: TEZ | 1.60 ± 0.951 | 1.76 ± 1.10 |
| Week 16: TEZ | 1.52 ± 0.701 | 1.80 ± 1.42 |
| Day 15: TEZ-M1 | 7.07 ± 1.08 | 7.07 ± 2.11 |
| Week 4: TEZ-M1 | 6.80 ± 1.64 | 7.09 ± 2.18 |
| Week 12: TEZ-M1 | 7.06 ± 2.37 | 7.18 ± 2.38 |
| Week 16: TEZ-M1 | 6.88 ± 1.94 | 6.95 ± 2.77 |
| Day 15: IVA | 0.549 ± 0.373 | 0.661 ± 0.552 |
| Week 4: IVA | 0.535 ± 0.402 | 0.594 ± 0.405 |
| Week 12: IVA | 0.383 ± 0.203 | 0.530 ± 0.474 |
| Week 16: IVA | 0.483 ± 0.347 | 0.580 ± 0.511 |
| Day 15: IVA-M1 | 1.47 ± 0.969 | 1.67 ± 0.961 |
| Week 4: IVA-M1 | 1.64 ± 1.29 | 1.52 ± 0.737 |
| Week 12: IVA-M1 | 1.19 ± 0.602 | 1.45 ± 0.907 |
| Week 16: IVA-M1 | 1.24 ± 0.673 | 1.51 ± 0.911 |
Sweat samples were collected using an approved collection device.
| millimole per liter (mmol/L) | Part B: ELX/TEZ/IVA |
|---|---|
| Part B: Absolute Change in Sweat Chloride (SwCl) | -57.9 (-61.3 to -54.6) |
The LCI2.5 index is the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting values and is calculated by dividing the sum of exhaled tidal breaths (cumulative exhaled volume (CEV)) by simultaneously measured functional residual capacity (FRC). An LCI of 7.5 and below is normal; values greater than 7.5 are abnormal. LCI is able to detect abnormalities in lung function earlier than more traditional modalities such as spirometry.
| index | Part B: ELX/TEZ/IVA |
|---|---|
| Part B: Absolute Change in Lung Clearance Index 2.5 (LCI 2.5) | -0.83 (-1.01 to -0.66) |
Collected over Day 1 Through Safety Follow-up Visit (up to Day 43 for Part A, up to Week 28 for Part B). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: ELX/TEZ/IVA | 0/18 (0%) | 0/18 (0%) | 15/18 (83.3%) |
| Part B: ELX/TEZ/IVA | 0/75 (0%) | 2/75 (2.7%) | 71/75 (94.7%) |
| Event | Part A: ELX/TEZ/IVA | Part B: ELX/TEZ/IVA |
|---|---|---|
| Anal incontinenceGastrointestinal disorders | 0/18 | 1/75 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 0/18 | 1/75 |
| Abnormal behaviourPsychiatric disorders | 0/18 | 1/75 |
| Urinary incontinenceRenal and urinary disorders | 0/18 | 1/75 |
| Event | Part A: ELX/TEZ/IVA | Part B: ELX/TEZ/IVA |
|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 4/18 | 46/75 |
| PyrexiaGeneral disorders | 1/18 | 26/75 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 3/18 | 25/75 |
| VomitingGastrointestinal disorders | 0/18 | 21/75 |
| COVID-19Infections and infestations | 0/18 | 14/75 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/18 | 13/75 |
| Alanine aminotransferase increasedInvestigations | 3/18 | 8/75 |
| RashSkin and subcutaneous tissue disorders | 2/18 | 12/75 |
| Upper respiratory tract infectionInfections and infestations | 1/18 | 11/75 |
| Decreased appetiteMetabolism and nutrition disorders | 0/18 | 9/75 |
All participants who received at least one dose of the study drug during the treatment period were included in the baseline analysis.
| Age, Categorical(Participants) | ELX/TEZ/IVA |
|---|---|
| Part A — <=18 years | 18 |
| Part A — Between 18 and 65 years | 0 |
| Part A — >=65 years | 0 |
| Part B — <=18 years | 75 |
| Part B — Between 18 and 65 years | 0 |
| Part B — >=65 years | 0 |
| Sex: Female, Male(Participants) | ELX/TEZ/IVA |
|---|---|
| Part A — Female | 11 |
| Part A — Male | 7 |
| Part B — Female | 41 |
| Part B — Male | 34 |
| Race/Ethnicity, Customized(Participants) | ELX/TEZ/IVA |
|---|---|
| Part A — Hispanic or Latino | 0 |
| Part A — Not Hispanic or Latino | 18 |
| Part A — Not collected per local regulations | 0 |
| Part B — Hispanic or Latino | 6 |
| Part B — Not Hispanic or Latino | 63 |
| Part B — Not collected per local regulations | 6 |
| Race/Ethnicity, Customized(Participants) | ELX/TEZ/IVA |
|---|---|
| Part A — White | 18 |
| Part A — Black or African American | 0 |
| Part A — Not collected per local regulations | 0 |
| Part B — White | 68 |
| Part B — Black or African American | 1 |
| Part B — Not collected per local regulations | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Ran from Nov 2020 to primary completion in Jun 2022, 18 months.
Results were first posted in Jun 2023, 1 year after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 18 months is below that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →